Abstract
The novel coronavirus disease 2019 (COVID-19) has become a matter of international concern as the disease is spreading exponentially. Statistics showed that infected patients in China who received combined treatment of Traditional Chinese Medicine and modern medicine exhibited lower fatality rate and relatively better clinical outcomes. Both Lian-Hua-Qing-Wen Capsule (LHQWC) and Jin-Hua-Qing-Gan Granule (JHQGG) have been recommended by China Food and Drug Administration for the treatment of COVID-19 and have played a vital role in the prevention of a variety of viral infections. Here, we desired to analyze the broad-spectrum anti-viral capacities of LHQWC and JHQGG, and to compare their pharmacological functions for rational clinical applications. Based on literature mining, we found that both LHQWC and JHQGG were endowed with multiple antiviral activities by both targeting viral life cycle and regulating host immune responses and inflammation. In addition, from literature analyzed, JHQGG is more potent in modulating viral life cycle, whereas LHQWC exhibits better efficacies in regulating host anti-viral responses. When translating into clinical applications, oral administration of LHQWC could be more beneficial for patients with insufficient immune functions or for patients with alleviated symptoms after treatment with JHQGG.
Highlights
Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule are Both Recommended as Effective “Chinese Solution” Against COVID-19The novel coronavirus disease 2019 (COVID-19) pandemics has reached almost every country in the world
Multi-ingredients, multi-targets and multi-pathways are primary features of Traditional Chinese Medicine (TCM) formulae, suggesting that active ingredients of one medicinal herb may exert anti-viral functions via diverse pharmacological mechanisms. Active components in both Lian-Hua-Qing-Wen Capsule (LHQWC) and Jin-Hua-Qing-Gan Granule (JHQGG) have been shown to target 87 different types of viruses, covering all the seven classes according to the Baltimore classification. This wide range of anti-viral activities of LHQWC and JHQGG addresses that TCM formulae used in COVID-19 pandemics could be potentially applied for other virological infections, such as influenza A virus, Zika virus and herpesvirus
Similarities and Differences of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule as Antivirals. Both LHQWC and JHQGG possess broad-spectrum anti-viral potentials through interfering with viral life cycle and modulating host immune responses, which are associated with a diversity of proposed pharmacological actions as detailed in Tables 1, 2, 3; Figure 2
Summary
Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule are Both Recommended as Effective “Chinese Solution” Against COVID-19The novel coronavirus disease 2019 (COVID-19) pandemics has reached almost every country in the world. The existence of a large number of asymptomatic carriers of SARS-CoV-2 exerts potential burden to the control and prevention of COVID-19. In spite of supportive measures above, potential anti-viral drugs which were used for diseases due to viral infections other than SARS-CoV-2 have been repurposed for COVID-19, such as remdesivir, ribavirin and hydroxychloroquine are not addressed because of reported side-effects or lack of supporting evidence from large-scale randomized controlled trials (Izcovich et al, 2020; Trivedi et al, 2020; Qaseem et al, 2021). Though tremendous strides have been made in the fight against coronaviruses, a lack of safe and effective anti-SARS-CoV-2 drugs is still a key factor restricting the prevention and control of COVID-19 pandemics
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
